Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Israel Business Currents.
Press releases published on September 3, 2025
PennantPark Floating Rate Capital Ltd. Announces Monthly Distribution of $0.1025 per Share
GlobeNewswire
·
September 3, 2025
MIAMI, Sept. 03, 2025 (GLOBE NEWSWIRE) -- PennantPark Floating Rate Capital Ltd. (the "Company") (NYSE: PFLT) declares its monthly distribution for September 2025 of $0.1025 per share, payable on October 1, 2025 to stockholders of record as of September 15 …
Printdash Takes the Worry Out of Online Order Commitments with Apollo Mass Digital Production from Kornit Digital
GlobeNewswire
·
September 3, 2025
US-based printed textile producer for top online stores makes fast, quality, custom apparel possible using three Kornit on-demand print production solutions Kornit Apollo and Atlas MAX PLUS systems form foundation of the Printdash business, accelerating …
SaverOne Signs Agreement with Fandango to Deploy its Driver Distraction Prevention Solution Across Heavy Truck Fleet
GlobeNewswire
·
September 3, 2025
Expands Presence in Heavy-Truck Sector, Reinforcing Strategic Penetration into High-Risk Commercial Fleets Petah Tikvah, Israel, Sept. 03, 2025 (GLOBE NEWSWIRE) -- SaverOne 2014 Ltd. (Nasdaq: SVRE, TASE: SVRE), a technology company specializing in …
Gilat Receives More Than $7 Million Order to Provide the U.S. DoD with Transportable SATCOM Terminals
GlobeNewswire
·
September 3, 2025
PETAH TIKVA, Israel, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Gilat Satellite Networks Ltd. (NASDAQ: GILT, TASE: GILT), a worldwide leader in satellite networking technology, solutions and services, announced today that Gilat DataPath (DataPath, Inc.) was …
Purple Biotech Expands CAPTN-3 Portfolio with IM1305, a Novel Tri-Specific Antibody Targeting TROP2
GlobeNewswire
·
September 3, 2025
Encouraging in-vivo results demonstrate sustained tumor regression with the CD3xTROP2xNKG2A antibody First CAPTN-3 tri-specific antibody, IM1240, targeting the novel tumor associated antigen 5T4 advances toward first-in-human clinical trials, with …